OBJECTIVE:Tamoxifen has antiestrogenic effects in the breast and estrogenlike activity in the skeletons of postmenopausal women. We hypothesized that postmenopausal women with breast cancer would experience a rapid decline in bone mineral density (BMD) after stopping tamoxifen, similar to that seen with estrogen withdrawal. The objective of this study was to assess, in a randomized, double-blind, placebo-controlled trial, whether administration of alendronate (70 mg weekly) would prevent bone loss associated with tamoxifen discontinuation. METHODS:Postmenopausal women with breast cancer were randomly assigned to receive alendronate or placebo for 1 year within 3 months after withdrawal of tamoxifen therapy. We initiated a randomized, double-blind, placebo-controlled trial of alendronate (70 mg weekly) in an effort to prevent bone loss associated with discontinuation of tamoxifen therapy. Patients treated with aromatase inhibitors were excluded from the study. BMD at the spine, hip, and forearm was measured at baseline and at 12 months. Analyses employed repeated-measures analysis of variance. RESULTS: Patient accrual was considerably limited by the substantial increase in use of aromatase inhibitors during the enrollment period. The study patients (N = 11) had similar baseline BMD T-scores in the alendronate (n = 6) and placebo (n = 5) subgroups. After 1 year, tamoxifen withdrawal was associated with a significant decline in BMD at the femoral neck, which appeared to be prevented by weekly administration of alendronate (-5.2% versus 0.1%; P = .02). Levels of urinary N-telopeptide, a marker of bone turnover, increased by 48% in study subjects in the placebo group (P < .01), whereas weekly alendronate treatment was associated with a 52% decline (P < .01) in this bone resorption marker. CONCLUSION: Differences in BMD and bone turnover were evident despite the small sample size. These data suggest that postmenopausal women with breast cancer completingtamoxifen therapy warrant an evaluation of their skeletal health and that bisphosphonate therapy may be useful in preventing bone loss associated with discontinuation of tamoxifen.
RCT Entities:
OBJECTIVE:Tamoxifen has antiestrogenic effects in the breast and estrogenlike activity in the skeletons of postmenopausal women. We hypothesized that postmenopausal women with breast cancer would experience a rapid decline in bone mineral density (BMD) after stopping tamoxifen, similar to that seen with estrogen withdrawal. The objective of this study was to assess, in a randomized, double-blind, placebo-controlled trial, whether administration of alendronate (70 mg weekly) would prevent bone loss associated with tamoxifen discontinuation. METHODS: Postmenopausal women with breast cancer were randomly assigned to receive alendronate or placebo for 1 year within 3 months after withdrawal of tamoxifen therapy. We initiated a randomized, double-blind, placebo-controlled trial of alendronate (70 mg weekly) in an effort to prevent bone loss associated with discontinuation of tamoxifen therapy. Patients treated with aromatase inhibitors were excluded from the study. BMD at the spine, hip, and forearm was measured at baseline and at 12 months. Analyses employed repeated-measures analysis of variance. RESULTS:Patient accrual was considerably limited by the substantial increase in use of aromatase inhibitors during the enrollment period. The study patients (N = 11) had similar baseline BMD T-scores in the alendronate (n = 6) and placebo (n = 5) subgroups. After 1 year, tamoxifen withdrawal was associated with a significant decline in BMD at the femoral neck, which appeared to be prevented by weekly administration of alendronate (-5.2% versus 0.1%; P = .02). Levels of urinary N-telopeptide, a marker of bone turnover, increased by 48% in study subjects in the placebo group (P < .01), whereas weekly alendronate treatment was associated with a 52% decline (P < .01) in this bone resorption marker. CONCLUSION: Differences in BMD and bone turnover were evident despite the small sample size. These data suggest that postmenopausal women with breast cancer completing tamoxifen therapy warrant an evaluation of their skeletal health and that bisphosphonate therapy may be useful in preventing bone loss associated with discontinuation of tamoxifen.
Authors: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater Journal: J Natl Cancer Inst Date: 2005-09-07 Impact factor: 13.506
Authors: Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch Journal: N Engl J Med Date: 2005-12-29 Impact factor: 91.245
Authors: Adam Brufsky; W Graydon Harker; J Thaddeus Beck; Robert Carroll; Elizabeth Tan-Chiu; Christopher Seidler; John Hohneker; Leo Lacerna; Stephanie Petrone; Edith A Perez Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Per E Lønning; Jürgen Geisler; Lars E Krag; Bjørn Erikstein; Yngve Bremnes; Anne I Hagen; Ellen Schlichting; Ernst A Lien; Erik S Ofjord; Jolanda Paolini; Anna Polli; Giorgio Massimini Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Richard Eastell; Rosemary A Hannon; Jack Cuzick; Mitch Dowsett; Glen Clack; Judith E Adams Journal: J Bone Miner Res Date: 2006-08 Impact factor: 6.741
Authors: R R Love; R B Mazess; H S Barden; S Epstein; P A Newcomb; V C Jordan; P P Carbone; D L DeMets Journal: N Engl J Med Date: 1992-03-26 Impact factor: 91.245
Authors: Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield Journal: J Clin Oncol Date: 2004-11-15 Impact factor: 44.544
Authors: Andrea Decensi; Zhuoxin Sun; Aliana Guerrieri-Gonzaga; Beat Thürlimann; Christina McIntosh; Carlo Tondini; Alain Monnier; Mario Campone; Marc Debled; Astrid Schönenberger; Khalil Zaman; Harriet Johansson; Karen N Price; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Stefan Aebi Journal: Breast Cancer Res Treat Date: 2014-02-01 Impact factor: 4.872
Authors: Evelyne Bischof; Fabienne D Schwab; Elena Laura Georgescu Margarint; Céline Montavon; Iris Zünti; Anna Schollbach; Andreas Schötzau; Anna Hirschmann; Julia Landin; Christian Meier; Kurzeder Christian; Marcus Vetter Journal: Bone Rep Date: 2021-12-11